New Stargardt Disease Treatment Improves Vision

CORAL SPRINGS, Fla. - Amzeal -- Stargardt Disease is the most common inherited macular degeneration, typically starting at a young age and progressively worsening to legal blindness.  This can affect many activities in a person's life, causing difficulty with reading, school, work, driving and seeing faces.  Eye doctors have not been able to offer any potential treatment for improvement- until now.  Just published, MD Stem Cells and the doctors conducting the Stem Cell Ophthalmology Treatment Study (SCOTS2) have released very encouraging data on patients with Stargardt Disease.

The Stem Cell Treatment Ophthalmology Study- both SCOTS and SCOTS2- has been treating many different eye diseases since 2013 using the patient's own bone marrow stem cells (BMSC).  The study is IRB approved and NIH registered on www.clinicaltrials.gov  NCT 03011541.  Different optic nerve and retinal diseases have shown benefit.  MD Stem Cells has worked to ascertain the safest, most effective approach to Stargardt Disease using BMSC - with gratifying success.

More on Amzeal News

• Concerned Citizens of South Central Los Angeles Send Open Letter To Biden Administration
• Footprint Project Partners with Clean Energy Leaders to Deploy Solar Energy Storage to Texas for Winter Storm Recovery
• Sandline Global Fortifies World-Class Executive Team: Glenn Hopper Joins as Chief Financial Officer
• RSTOR Enhances Software Defined Cloud Platform to Support Hybrid, Multi-Cloud Enterprise Infrastructures
• GBKSOFT reveals the benefits of Building Websites with PHP in 2021?

In the 34 eyes treated, vision improved in 61.8% and remained stable in 23.5%-  positive results in over 84% of eyes.  As might be expected, some eyes continued to worsen as a result of the disease. The results were highly statistically significant- meaning that the treatment was overwhelmingly likely to be responsible for the vision benefit. The average improvement across all eyes treated was 17.96% (95% CI, 16.39 to 19.53%).  Reviewing the overall results, 76.5% of patients showed improvement in one or both eyes, 17.6% showed no net loss and only 1 patient continued to worsen from their disease- so improvement or stability in over 94% of patients.  This is similar, although not quite as strong, to the results in dry Age Related Macular Degeneration.

" This makes sense given that both are primarily diseases of the macula or central part of the retina" says Dr. Levy, Chair and Study Director for SCOTS2. " We can postulate that one way the BMSC may benefit the central vision by helping this layer of the retina".

SCOTS and now SCOTS2 have been evaluating BMSC in the treatment of optic nerve and retinal disease for over 7 years.  The physicians involved with MD Stem Cells now have 15 world class medical and scientific publications primarily in ophthalmology, but also regarding their neurology study. This is vastly more than any other stem cell research group in this field- which is important to patients seeking experienced providers.

More on Amzeal News

• Syxsense Announces Integration with Microsoft Office 365
• Launch of Trace One E-Sourcing Will Boost Retailers' Private Label Speed to Market
• Australian Content Farm Kantado gets its first US hit single
• New Video Streaming Startup, Relax Scenes, Launches Indiegogo Campaign to Support Their Expansion
• Bronx DWI Lawyer Announces New Website

Dr. Levy concludes: "as we continue SCOTS 2, we can conclude that patients with Stargardt Disease choosing to participate in the study have a strong likelihood of either improving or stabilizing their vision. "

Patients may receive information about SCOTS 2 by emailing Dr. Levy below , using the contact us page on www.mdstemcells.com, or calling 203-423-9494. The Stem Cell Ophthalmology Study 2 is enrolling patients with different retina and optic nerve diseases. MD Stem Cells has no grant support and is not a pharmaceutical company; these are patient sponsored studies and the patients pay for both treatment and travel.